• Vasomotor symptoms have been proposed as markers of changing cardiovascular risk.
Essentials
• Vasomotor symptoms have been proposed as markers of changing cardiovascular risk.
• In this cohort study, we evaluated these symptoms as markers of venous thrombosis (VT) risk.
• We found no evidence that vasomotor symptom presence or severity were associated with VT risk.
• Among these postmenopausal women, vasomotor symptoms are not a useful marker of VT risk.
Summary. Background: Vasomotor symptoms may be markers of changes in cardiovascular risk, but it is unknown whether these symptoms are associated with the risk of venous thrombosis (VT). Objective: To evaluate the association of vasomotor symptom presence and severity with incident VT risk among postmenopausal women, independent of potential explanatory variables. Methods: This cohort study included participants of the Women's Health Initiative (WHI) Hormone Therapy Trials (n = 24 508) and Observational Study (n = 87 783), analyzed separately. At baseline, women reported whether hot flashes or night sweats were present and, if so, their severity. Using Cox proportional hazards models, we estimated the VT risk associated with vasomotor symptom presence and severity, adjusted for potential explanatory variables: age, body mass index, smoking status, race/ethnicity, and time-varying current hormone therapy use. Results: At baseline, WHI Hormone Therapy Trial participants were aged 64 years and WHI Observational Study participants were aged 63 years, on average. In the WHI Hormone Therapy Trials over a median of 8.2 years of follow-up, 522 women experienced a VT event. In the WHI Observational Study, over 7.9 years of follow-up, 1103 women experienced a VT event. In adjusted analyses, we found no evidence of an association between vasomotor symptom presence (hazard ratio 
Introduction
Although a large proportion of postmenopausal women experience hot flashes or night sweats, known as vasomotor symptoms [1] , the severity, timing and duration of these symptoms vary. This interindividual variability has led to the hypothesis that vasomotor symptoms may serve as a marker of underlying vascular change, and thus of cardiovascular event risk [2] . Given that endogenous hormone levels are thought to be associated with vasomotor symptoms [3] [4] [5] , and the strong association between the use of oral exogenous hormones and venous thrombosis (VT) risk [6] [7] [8] [9] [10] [11] , it is plausible that these symptoms may constitute a marker of hormonally related vascular changes that could ultimately impact on VT risk. However, whether vasomotor symptoms are associated with the risk of VT events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), remains unclear.
Our objective was to characterize the risk of incident VT associated with vasomotor symptom presence, severity, timing, and duration, independent of potential explanatory variables, in a cohort of postmenopausal women. We hypothesized that vasomotor symptom presence and greater vasomotor symptom severity would be associated with a greater risk of incident VT, and, in secondary analyses, that later menopausal status at vasomotor symptom onset and longer vasomotor symptom duration would be positively associated with VT risk.
Methods

Study and design
This analysis includes data from two prospective studies within the Women's Health Initiative (WHI): the WHI Hormone Therapy Trials and the WHI Observational Study [12] . The WHI studies were approved by human subjects review committees at each participating institution, and participants provided written informed consent.
Eligible participants
From all WHI Hormone Therapy Trial (n = 27 347) and WHI Observational Study (n = 93 676) participants, we excluded women who were missing baseline vasomotor symptom data (WHI Hormone Therapy Trials, n = 163; WHI Observational Study, n = 516), had a history of VT (WHI Hormone Therapy Trials, n = 312; WHI Observational Study, n = 4135), were missing the number of days of follow-up (WHI Hormone Therapy Trials, n = 92; WHI Observational Study, n = 474), were using anticoagulants (WHI Hormone Therapy Trials, n = 1; WHI Observational Study, n = 1115), and who, in the WHI Hormone Therapy Trials, had not completed a full 3-month period of hormone therapy (HT) washout by time of vasomotor symptom report (n = 2273).
Vasomotor symptoms
At baseline, women reported whether they had experienced hot flashes or night sweats in the previous 4 weeks, and, if so, whether they were mild (did not interfere with usual activities), moderate (interfered somewhat), or severe (usual activities could not be performed). Analyses evaluating menopausal status at vasomotor symptom onset and vasomotor symptom duration relied on selfreported data regarding age at the time of first and last vasomotor symptoms and age at menopause [13] . We classified vasomotor symptom onset as occurring in premenopause/perimenopause, the year of menopause, or postmenopause. Vasomotor symptom duration as of baseline was calculated by subtracting age at first from age at last vasomotor symptoms, or from age at baseline if still present.
VT
In the WHI Hormone Therapy Trials, participants reported inpatient and outpatient VT events every 6 months and at annual visits until 8 April 2005. Possible VT events were reviewed by trained adjudicators [8, 14] . In the WHI Observational Study, inpatient and outpatient VT events were self-reported annually in years 1 and 3-8 until 12 September 2005 and were not adjudicated.
Other characteristics
At baseline, participants completed questionnaires about demographics, lifestyle, and medical history [12] , including age, race/ethnicity, age at last menstruation, hysterectomy/oophorectomy, smoking, education, and physical activity. Participants reported whether they had treated diabetes, high cholesterol, physician-diagnosed hypertension, or a family history of VT. Baseline weight and height were measured and used to calculate body mass index (BMI) in kg m
À2
. At baseline, which was prior to the start of the trial's 3-month HT washout and subsequent HT randomization, both cohorts reported current and prior use of HT, including pills, patches, implants, creams, suppositories, shots, and birth control pills, used after age 50 years. During follow-up, WHI Hormone Therapy Trial participants reported adherence to the trial's randomized treatment, and participants of the WHI Observational Study reported the use of HT on annual follow-up forms.
Statistical analyses
In primary analyses, separate Cox proportional hazards models stratified by time-varying risk-set strata of current HT use (any versus none) were used to evaluate the association of baseline vasomotor symptom presence (absence as referent) and, among women with current vasomotor symptoms, severity (mild as referent) with time to VT event. In secondary analyses among those with vasomotor symptoms, similar models were used to separately evaluate the association of menopausal status at the time of first vasomotor symptoms (premenopause/ perimenopause as referent) and vasomotor symptom duration as of baseline (< 5 as referent), with time to VT event.
Time-to-event was defined as the number of days from randomization in the WHI Hormone Therapy Trials and the number of days from enrollment in the WHI Observational Study to first VT diagnosis, with removal from observation at the earliest date of death, loss to followup, or end of follow-up. Analysis of the relationships between VT risk and vasomotor symptom severity, menopausal status at onset, and duration included a test for linear trend using grouped linear variables. Statistical significance was determined with a Bonferroni-adjusted twosided a level of 0.0125 (0.05/4 total vasomotor symptom exposures).
For all vasomotor symptom exposures, we used both age-adjusted and multivariable-adjusted models that included potential explanatory variables identified a priori to evaluate whether vasomotor symptoms may be associated with VT risk independent of several well-characterized and clinically utilized VT risk factors: age, BMI, smoking (never, former, and current), and race/ethnicity (White not of Hispanic origin, Black or African-American, and other). A sensitivity analysis adjusted for additional factors that are sometimes used to screen for cardiovascular risk: hypertension, hyperlipidemia, bilateral salpingo-oophorectomy (BSO), and family history of VT. An additional model further adjusted for physical activity and education.
Covariates with missing data (BMI [ [15, 16] . Given the relationships between late-onset vasomotor symptoms and other cardiovascular event outcomes [2] , we evaluated the interactions hypothesized a priori between vasomotor symptom presence and baseline age group (50-59, 60-69 and 70-79 years) and, separately, years since menopause (< 10, 10-19 and ≥ 20 years) by using likelihood ratio tests. Sensitivity analyses for vasomotor symptom presence and severity excluded women with current baseline HT use (695 excluded in the WHI Hormone Therapy Trials; 42 347 excluded in the WHI Observational Study), and analyses for menopausal status at vasomotor symptom onset and vasomotor symptom duration excluded women with any baseline or prior HT use (10 260 excluded in WHI Hormone Therapy Trials; 60 171 excluded in the WHI Observational Study). Further sensitivity analyses subclassified women without vasomotor symptoms present at baseline into women with past vasomotor symptoms and those who had never had vasomotor symptoms to evaluate the VT risk associated with currently having vasomotor symptoms, having had vasomotor symptoms in the past, and never having had vasomotor symptoms.
Results and discussion
The eligible study population included 24 508 WHI Hormone Therapy Trial and 87 783 WHI Observational Study participants, with average follow-up periods of 8.1 years and 7.5 years, respectively. Women with severe hot flashes were more likely to have had a prior BSO, to have been hypertensive, to have diabetes, to be current smokers, and to be Black, and less likely to have a college degree, than were women without severe vasomotor symptoms (Table 1) .
In adjusted analyses, we found no evidence of an association between vasomotor symptom presence and risk of a VT event in the WHI Hormone Therapy Trials (hazard ratio [HR] Table 2 ). Among women with vasomotor symptoms, there was no evidence of an association between VT risk and vasomotor symptom severity (WHI Hormone Therapy Trials P-trend = 0.62; WHI Observational Study P-trend = 0.55; Table 2 ), menopausal status at vasomotor symptom onset (WHI Hormone Therapy Trials P-trend = 0.23; WHI Observational Study Ptrend = 0.13), or vasomotor symptom duration (WHI Hormone Therapy Trials P-trend = 0.42; WHI Observational Study P-trend = 0.33) ( Table 3) . We found no evidence of an interaction between vasomotor symptom presence and age group (WHI Hormone Therapy Trials likelihood ratio test P = 0.16; WHI Observational Study P = 0.45) or years since menopause (WHI Hormone Therapy Trials P = 0.50; WHI Observational Study P = 0.12) regarding VT risk.
In sensitivity analyses adjusted for additional possible explanatory variables, effect estimates were similar to those in primary analyses and remained non-significant. When women using HT at baseline were excluded, there remained no evidence of an association between VT risk and vasomotor symptom presence in the WHI Hormone Therapy Trials (HR adj 0.94; 95% CI 0.78-1.1) or WHI Observational Study (HR adj 1.2; 95% CI 0.97-1.4) or between VT risk and vasomotor symptom severity. In sensitivity analyses of menopausal status at vasomotor symptom onset that excluded women who reported any current or past HT, estimates of VT risk associated with postmenopausal status at vasomotor symptom onset did not change. Sensitivity analyses of vasomotor symptom duration with current and past HT users excluded provided estimates similar to those in the primary analysis. .7) 11.7 (14.1)
(13.4)
BMI, body mass index; E, estrogen; HT, hormone therapy; MET, metabolic equivalent of task; P, progestogen; SD, standard deviation; VT, venous thrombosis; WHI, Women's Health Initiative.
In further analyses that subdivided women without current vasomotor symptoms into those never having had symptoms and those having had symptoms in the past, point estimates for VT risk associated with past vasomotor symptoms were similar to those for current vasomotor symptoms, and were similarly null.
In this study of postmenopausal participants, we found no evidence of an association between vasomotor symptom presence, severity, timing or duration and VT risk. To our knowledge, no studies have evaluated the association between vasomotor symptoms and VT risk, and few have investigated the association of vasomotor symptoms with other cardiovascular disease clinical endpoints [2, 17, 18] . The presence of night sweats, but not hot flashes, was associated with a modestly greater risk of coronary heart disease (CHD) than vasomotor symptom absence in a population-based study of women aged 46-64 years (HR adj 1.3; 95% CI 1.1-1.7) [17] . In a prior WHI Observational Study analysis, timing of vasomotor symptoms was important; women with early vasomotor symptoms had a 17% lower risk of stroke and an 11% lower risk of arterial cardiovascular events, whereas women with later onset of vasomotor symptoms had a 30% higher risk of major CHD, than women who had never reported vasomotor symptoms [2] . Although effect estimates in our study associated with vasomotor symptom onset in postmenopause were similar to these published estimates for CHD [2] , the association between vasomotor symptom timing and VT risk was not statistically significant. It is plausible that differences in the etiologies of arterial thrombosis and VT may explain differences in the association. A recent cross-sectional study set in the WHI Hormone Therapy Trials suggested no convincing evidence of an association between vasomotor symptoms and hemostatic parameter levels, which are markers of thrombotic risk, supporting the plausibility of vasomotor symptoms not being markers of VT event risk [19] . The vasomotor symptom data used in this study were self-reported, and included only a single measurement of current symptoms in postmenopause, which limits our ability to evaluate vasomotor symptoms earlier in the menopausal transition in relation to VT risk. Although self-reported vasomotor symptom data are easy and inexpensive to collect clinically, and reflect a woman's perception of her symptoms, they are also subjective. Other limitations include the retrospective reporting of vasomotor symptom characteristics. Women may inaccurately recall age at first vasomotor symptoms, given that most participants were in late menopause at baseline (average age of 64 years in the WHI Hormone Therapy Trials; average age of 63 years in the WHI Observational Study), but we have no reason to believe that misclassification would differ by VT risk. In addition, whereas VT events were adjudicated in the WHI Hormone Therapy Trials, events were self-reported in the WHI Observational Study, which will introduce misclassification. A validation study in WHI Hormone Therapy Trials reported that, as compared with adjudication, selfreported DVT and PE had positive predictive values of 64% and 90%, respectively [14] , suggesting that WHI Observational Study self-reported VT events may include only moderate levels of misclassification. Misclassification of the outcome may bias WHI Observational Study results towards the null.
A complicating factor in this study is the use of oral HT, which is known to be associated with an increased risk of VT [8] , and which also effectively reduces vasomotor symptoms in most women. In this study, we stratified analyses by time-varying current HT. Prior use of HT may alter the age at first and last vasomotor symptoms, but relative risk estimates from sensitivity analyses that excluded current and past HT users were generally similar to full cohort estimates. Women eligible for these sensitivity analyses may not be representative of the general population, as women with vasomotor symptoms who choose not to use HT might have a different cardiovascular risk from women with vasomotor symptoms who choose to use HT.
Owing to the unique setting of the WHI, which included both observational and randomized HT trial components, we were able to conduct our analyses in two populations with similar data collected. Analyses were conducted separately because of differences in the use of HT at baseline by vasomotor symptoms. Among women without vasomotor symptoms at baseline, only 2% used HT at baseline prior to washout in the WHI Hormone Therapy Trials, as compared with 52% in the WHI Observational Study. Other strengths include a large number of participants, our ability to evaluate vasomotor symptom severity, duration, and timing in addition to vasomotor symptom presence, and the adjudication of VT events in the WHI Hormone Therapy setting.
In summary, although vasomotor symptoms have been previously associated with a greater risk of CHD and allcause mortality [2, 17] , we found no evidence that vasomotor symptom presence, severity, timing or duration was associated with VT incidence. For VT, self-reported vasomotor symptoms do not appear to be useful markers of event risk. in this manuscript are those of the authors, and do not necessarily reflect the views of the National Heart, Lung, and Blood Institute/US Department of Health and Human Services.
